Notably, the immunosuppressive protocol was based on calcineurin inhibitors and MMF. and the remaining were bad (Group-2). Graft loss at 6?weeks was higher in Group-1 (12.5 vs. 4.2% test in scaled variables with two groups. Probabilities less than 0.05 were considered significant. Survival was determined using the KaplanCMeier Method and differences between the distributions of survival were assessed with the log-rank test. Multivariate analyzes of graft loss and graft thrombosis-associated variables were performed using Cox regression (proportional risks model). The relative measure of an effect was indicated as hazard percentage (HR). Multivariate analysis of DGF (dichotomous end result concentrated in a very short period of time) was performed using logistic regression model (19). Probabilities less than 0.05 were considered significant. The policy concerning donorCrecipient selection was based on trying to match recipients and donors with related age groups. Therefore, donor age is definitely a recipient age-dependent variable. Donor age was not included like a statistical analysis variable except when studying DGF because it is definitely more associated with donor age than recipient age in the literature (20). Data were processed and analyzed using Medcalc for Windows version 16.1 (MedCalc Software, Ostend, Belgium). Results Antiphospholipid Antibodies The average pretransplant levels of aCL antibodies were IgM 5.4?U/mL??0.7 and IgG 4.0?U/mL??0.4. Mean levels of abdominal2GP1 antibodies were as follows: IgM 4.3?U/mL??0.8, IgG were 4.1?U/mL??0.5, and IgA were 32.4?U/mL??1.8 (Table S2 in Supplementary Material). Individuals whose antibody levels were above the cutoff were regarded as positive. Prevalence of aCL positive individuals was 1.1% Mouse monoclonal to ROR1 for IgM and 1.2% for IgG. Prevalence of aB2GP1 antibodies individuals was 1.6% for IgM and 1.2% for IgG. Individuals with IgA-aB2GP1 Antibodies Two hundred eighty-eight (38.9%) individuals NQDI 1 were positive for IgA-aB2GP1 antibodies (Group-1) and 452 were negative (Group-2). Individuals in Group-1, were immunologically less complex and there were fewer retransplanted individuals (10.8 vs. 17.5%; p?=?0.017) and less hyperimmunized individuals (6.6 vs. 11.9%; p?=?0.024). The prevalence of dyslipidemia and hypertension was slightly higher in Group-1. The remaining pretransplant characteristics did not differ between both organizations (Table ?(Table1).1). The correlation between recipient age and IgA-aB2GP1 levels was very poor (Correlation coefficient r?=?0.184, 95% CI: 0.114C0.253). Table 1 Pretransplant condition of individuals in Group-1 (positive for IgA-aB2GP1 antibodies) and in Group-2 (bad individuals).
Sex (ladies)10737.2%19843.8%N.S.Age (years)a51.90.847.40.6<0.001Donor age (years)a47.9144.20.8N.S.Body mass indexa25.50.324.90.2N.S.Time on dialysis (weeks)a36.52.228.82.0N.S.
Type of dialysis??Hemodialysis21775.3%34275.7%N.S.??Peritoneal dialysis5820.1%10022.1%N.S.??Both124.2%81.8%N.S.??Undialyzed10.3%20.4%N.S.Panel reactive antibody score (PRA) at transplantation >50%51.7%194.2%N.S.Historic PRA >50%196.6%5411.9%0.024Previous kidney transplant3110.8%7917.5%0.017Caged ischemia (h)a19.50.319.80.3N.S.
Associated conditions Diabetes mellitus??Type 1 diabetes144.9%173.8%N.S.??Type 2 diabetes227.6%245.3%N.S.Dyslipidemia9031.2%9821.7%0.004Hypertension23079.9%31168.8%0.001
Causes CKD??Chronic glomerulonephritis7325.313730.3%N.S.??Interstitial kidney disease4114.2%5913.1%N.S.??Nephroangiosclerosis206.9%408.8%N.S.??Polycystic kidney disease4716.3%7115.7%N.S.??Diabetes mellitus279.4%296.4%N.S.??Unfamiliar4515.6%6714.8%N.S.??Others3512.2%4910.8%N.S. Open in a separate windows N.S., non-significant. aMannCWhitney test was used because variable is not normally distributed. Clinical Events and Program in the Early Posttransplant Period (6?Weeks) Thirty-six individuals NQDI 1 in Group-1 (12.5%) lost their graft during the first semester after transplantation vs. 19 in the Group-2 (4.2%, p?p?p?p?p?p?=?0.001) (Table ?(Table3).3). As the risk of graft loss and graft thrombosis is definitely partially dependent on the donor factors, we performed an analysis of same-donor combined NQDI 1 kidneys (21) showing the same results (data not demonstrated). Table 2 Posttransplant events of individuals in Group-1 (positive for IgA-aB2GP1 antibodies) and in Group-2 (bad individuals).
Delayed graft function (DGF)10335.8%8819.5%<0.001Graft loss on the complete follow-up (global 29.6%)11439.6%10523.2%<0.001??First-month (global 3.9%)206.9%92%0.001??First-trimester (global 5.9%)3110.8%132.9%<0.001??1st semester (global 7.4%)3612.5%194.2%<0.001??1st year (global 8.5%)3813.2%255.5%<0.001
Causes graft loss 1st semesterAcute rejection (AR)72.4%10.2%0.014Non-functioning graft10.3%61.3%N.S.Death (having a functioning kidney)41.4%40.9%N.S.??Cardiovascular diseases (CVDs)10N.S.??Infections30N.S.??Sudden.
